| Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations FW Huang, JM Mosquera, A Garofalo, C Oh, M Baco, A Amin-Mansour, ... Cancer discovery 7 (9), 973-983, 2017 | 124 | 2017 |
| Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview AKB Alme, BS Karir, BM Faltas, CG Drake Urologic Oncology: Seminars and Original Investigations 34 (4), 171-181, 2016 | 49 | 2016 |
| Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). ST Tagawa, J Batra, S Vallabhajosula, Y Jhanwar, PJ Christos, ... Journal of Clinical Oncology 34 (15_suppl), 5022-5022, 2016 | 12 | 2016 |
| Antibody therapeutics for treating prostate cancer: where are we now and what comes next? PJ Vlachostergios, G Galletti, J Palmer, L Lam, BS Karir, ST Tagawa Expert Opinion on Biological Therapy 17 (2), 135-149, 2017 | 10 | 2017 |
| Clipless robotic-assisted radical prostatectomy and impact on outcomes SP Basourakos, A Zhu, PJ Lewicki, A Ramaswamy, E Cheng, V Dudley, ... European Urology Focus 8 (5), 1176-1185, 2022 | 9 | 2022 |
| Novel molecular targets for urothelial carcinoma BM Faltas, BS Karir, ST Tagawa, JE Rosenberg Expert opinion on therapeutic targets 19 (4), 515-525, 2015 | 9 | 2015 |
| Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic … JS Batra, BS Karir, S Vallabhajosula, PJ Christos, G Hodes, PR Date, ... Journal of Clinical Oncology 33 (7_suppl), 194-194, 2015 | 6 | 2015 |
| DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177LU-J591) FOR MCRPC: MP50-19 JS Batra, B Karir, K Pinto-Chengot, YS Jhanwar, S Vallabhajosula, ... Journal of Urology 195 (4), e680, 2016 | 5 | 2016 |
| The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer E Diamond, M del Carmen Garcias, B Karir, ST Tagawa Current treatment options in oncology 16, 1-15, 2015 | 4 | 2015 |
| Paraneoplastic limbic encephalitis as initial presentation of testicular neoplasm: A case report C Chen, A Nadeem, B Karir, HH Shohet, K Babagbemi Clinical Imaging 76, 61-64, 2021 | 2 | 2021 |
| Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration … AM Molina, JS Batra, BS Karir, Y Jhanwar, S Vallabhajosula, PJ Christos, ... Cancer Research 76 (14_Supplement), CT140-CT140, 2016 | 1 | 2016 |
| MP33-19 INTRADUCTAL CARCINOMA OF THE PROSTATE IN THE ERA OF MPMRI-TARGETED PROSTATE BIOPSIES: CLINICAL, PATHOLOGIC AND MRI CHARACTERISTICS J Fainberg, C Chen, J Chen, A Balasubramanian, C Barbieri, L Dreyfus, ... Journal of Urology 207 (Supplement 5), e577, 2022 | | 2022 |
| MP26-09 INTRADUCTAL CARCINOMA OF THE PROSTATE IN THE ERA OF MPMRI-TARGETED PROSTATE BIOPSIES: ARE WE MAKING AN IMPACT? J Fainberg, B Karir, F Khani, J Tu, JM Mosquera, H Nagar, C Barbieri, ... Journal of Urology 206 (Supplement 3), e465-e466, 2021 | | 2021 |
| Whole Exome Sequencing of Carcinosarcoma from Distinct Primary Sites Reveals Potential Targetable Genomic Alterations S Beg, B Karir, K Eng, F Khani, B Robinson, A Sboner, O Elemento, ... LABORATORY INVESTIGATION 99, 2019 | | 2019 |
| Precision Medicine in Prostate Cancer: Approach to the Patient BS Karir, BM Faltas, ST Tagawa Precision Molecular Pathology of Prostate Cancer, 3-12, 2018 | | 2018 |
| Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC) K Pinto-Chengot, Y Jhanwar, J Batra, B Karir, S Vallabhajosula, ... Cancer Research 76 (14_Supplement), 3971-3971, 2016 | | 2016 |
| Pilot study of" hyperfractionated" anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate … AM Molina, JS Batra, BS Karir, Y Jhanwar, S Vallabhajosula, PJ Christos, ... CANCER RESEARCH 76, 2016 | | 2016 |
| Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer. BS Karir, PJ Vlachostergios, PJ Christos, VRA Febles, K Pinto-Chengot, ... Journal of Clinical Oncology 34 (2_suppl), 268-268, 2016 | | 2016 |
| Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu−J591) for progressive metastatic castration … JS Batra, BS Karir, K Pinto-Chengot, Y Jhanwar, S Vallabhajosula, ... Journal of Clinical Oncology 34 (2_suppl), 205-205, 2016 | | 2016 |
| Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer P Date, BS Karir, JS Batra, Y Jhanwar, H Beltran, DM Nanus, NH Bander, ... CANCER RESEARCH 75, 2015 | | 2015 |
